• About Us
  • Our Editorial Policy
  • Business Directory
  • Advertise with Us
  • Our Advertisers
  • Contact Us
Australia India News
India News Australia
  • Home
  • Current Issue
    Past Issue
  • India News
  • Politics
  • Business
  • World
    World This Week
  • Community News
  • What's On
  • Others
    Yoga in Australia News COVID-19 Community News Naari IPL News Health Travel Entertainment
  • Migrants Expo
  • National Events
  • Please wait..
India News News

NCB secures 7-year jail for three who diverted chemicals for drug-making

  • BY India News Newsdesk
  • January 13, 2026
  • 0 COMMENTS

Ahmedabad, Jan 12 (IANS) A Special NDPS Court in Gujarat sentenced three convicts to seven years rigorous imprisonment in a case related to diversion of pharmaceutical precursors used in illicit drug manufacturing, a Narcotics Control Bureau official said on Monday.

The Court at Savarkundla, District Amreli, Gujarat, convicted Alps Life Sciences Pvt Ltd, Sonipat, Haryana, and its three senior functionaries, who were also slapped a penalty of Rs 1.5 lakh each, said the NCB official in a statement.

The investigation revealed deliberate falsification of manufacturing and export records and active involvement of senior company officials.

Those convicted in the case are Sumit Kumar, Managing Director, Sumit Kumar, Store In-charge, Dhanesh Chamoli, Authorised Chief Chemist-cum-Production Manager, and the company, Alps Life Sciences itself.

The case was registered under Sections 9A read with 25A, 26, 29, 35 and 38 of the NDPS Act, 1985, and relevant provisions of the NDPS (Regulation of Controlled Substances) Order, 2013.

The case was investigated by the NCB Ahmedabad Zonal Unit and pertains to the diversion of pseudoephedrine, a controlled substance under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985.

The complaint against the accused persons and the company was filed before the court on November 24, 2023.

During the investigation and trial, the accused sought bail from various judicial fora, including the Supreme Court of India. However, considering the seriousness of the offence, the transnational ramifications of precursor diversion, and the strong evidentiary foundation laid by NCB, the bail pleas were not accepted, underscoring the gravity of the crime.

This conviction sends a strong message that diversion of pharmaceutical precursors and misuse of legitimate drug manufacturing channels will not be tolerated. The successful outcome reflects NCB’s professional investigation, inter-agency coordination and sustained legal follow-up, and reinforces its commitment to dismantling drug supply chains, said the statement.

–IANS

rch/dan

Post navigation

Delhi Minister Sirsa attacks Atishi, Kejriwal for ‘disrespecting’ Sikh Gurus
Youth power will shape India’s future: Tripura CM Manik Saha

Related Post

No action from IT Ministry on Rahul Gandhi’s social media posts, claims bogus: Sources
May 11, 2026
Madhya Pradesh gets Rs 3,818cr package under PMGSY and PMAY-G schemes
May 11, 2026
Gujarat: PM Modi receives grand welcome in Jamnagar, participates in public meeting
May 11, 2026
Gujarat: Bengali residents gather ahead of PM Modi’s arrival, voice hope for Bengal’s development
May 11, 2026

Our Current Issue

Australia India News – May 1-15, 2026

Our Advertisers

  • Battery Rebate australia
  • Bess Australia Solar Panels

Follow Us

  • facebook
  • facebook
  • facebook
  • facebook
INDIA NEWS on YouTube in Australia, bring to our readers and subscribers national and international news, editorials, expert columns, community activities and interviews of political leaders, celebrities, business professionals, academics and sport personalities among others.
  • facebook
  • facebook
  • facebook
  • facebook

Category

  • Accident
  • Adani Australia
  • Advertorial
  • Arts & Culture
  • Ashes 2022
  • Australia

Recent News

  • Sr Open Ranking Wrestling: Deepak Punia advances...
  • No action from IT Ministry on Rahul Gandhi’s...

Subscribe Newsletter

Get the latest creative news from india news

  • Privacy Policy
  • Disclaimer